VINCERX PHARMA INC (VINC) Stock Price, Quote, News and Overview
NASDAQ:VINC - Nasdaq - US92731L3042 - Common Stock - Currency: USD
VINC Quote, Performance and Key Statistics
0.275
+0.02 (+7.34%)
The current stock price of VINC is 0.275 USD. In the past month the price decreased by -61.76%. In the past year, price decreased by -98.38%.
VINC Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.09 | 306.02B | ||
| AMGN | AMGEN INC | 13.99 | 149.08B | ||
| GILD | GILEAD SCIENCES INC | 22.68 | 130.32B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1686.55 | 125.74B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.34 | 61.56B | ||
| ARGX | ARGENX SE - ADR | 318.82 | 36.23B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 30.51B | ||
| ONC | BEIGENE LTD-ADR | N/A | 24.88B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.74B | ||
| NTRA | NATERA INC | N/A | 20.02B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.15B | ||
| BIIB | BIOGEN INC | 7.2 | 17.36B |
Related stock screener links
About VINC
Company Profile
Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company which develops antibody drugs. The company is headquartered in Palo Alto, California and currently employs 42 full-time employees. The company went IPO on 2020-03-10. The firm is focused on developing differentiated and novel therapies to address the unmet medical needs of patients with cancer. The company has a next generation bioconjugation platform, called VersAptx. The VersAptx platform is a versatile and adaptable, next generation bioconjugation platform. Its product candidates include VIP943 (CD123-KSPi), VIP924 (CXCR5-KSPi), VIP236, and Enitociclib (P-TEFb/CDK9 inhibitor). VIP943 is a potential anti-CD123 ADC created with its VersAptx Platform. The company consists of an anti-CD123 antibody, a novel legumain-cleavable linker, and a KSPi payload enhanced with its CellTrapper technology. Enitociclib is a selective CDK9 inhibitor. Enitociclib effectively blocks P-TEFb-mediated activation of RNA polymerase II, preventing transcription of MCL1 and MYC, proteins associated with poor prognosis in various types of cancer.
Company Info
VINCERX PHARMA INC
260 Sheridan Avenue, Suite 400
Palo Alto CALIFORNIA 94306 US
CEO: Ahmed M. Hamdy
Employees: 42
Company Website: https://vincerx.com/
Investor Relations: https://investors.vincerx.com/
Phone: 16508006676
VINCERX PHARMA INC / VINC FAQ
What is the stock price of VINCERX PHARMA INC today?
The current stock price of VINC is 0.275 USD. The price increased by 7.34% in the last trading session.
What is the ticker symbol for VINCERX PHARMA INC stock?
The exchange symbol of VINCERX PHARMA INC is VINC and it is listed on the Nasdaq exchange.
On which exchange is VINC stock listed?
VINC stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for VINCERX PHARMA INC stock?
7 analysts have analysed VINC and the average price target is 204 USD. This implies a price increase of 74081.82% is expected in the next year compared to the current price of 0.275. Check the VINCERX PHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is VINCERX PHARMA INC worth?
VINCERX PHARMA INC (VINC) has a market capitalization of 1.44M USD. This makes VINC a Nano Cap stock.
How many employees does VINCERX PHARMA INC have?
VINCERX PHARMA INC (VINC) currently has 42 employees.
What are the support and resistance levels for VINCERX PHARMA INC (VINC) stock?
VINCERX PHARMA INC (VINC) has a resistance level at 0.47. Check the full technical report for a detailed analysis of VINC support and resistance levels.
Should I buy VINCERX PHARMA INC (VINC) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of VINC, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of VINC, evaluating the profitability, health, valuation and growth aspects
- VINCERX PHARMA INC (VINC) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- VINCERX PHARMA INC (VINC) Sales and EPS estimates to see what analysts future expectations are.
- VINCERX PHARMA INC (VINC) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- VINCERX PHARMA INC (VINC) Insider and Institutional Ownership to learn about the owners and their transactions.
- VINCERX PHARMA INC (VINC) Stock Chart to make your own analysis
- VINCERX PHARMA INC (VINC) Latest news and press-releases to stay up to date.
Does VINCERX PHARMA INC (VINC) stock pay dividends?
VINC does not pay a dividend.
When does VINCERX PHARMA INC (VINC) report earnings?
VINCERX PHARMA INC (VINC) will report earnings on 2025-05-12.
What is the Price/Earnings (PE) ratio of VINCERX PHARMA INC (VINC)?
VINCERX PHARMA INC (VINC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-20.2).
VINC Technical Analysis
VINC Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to VINC. While VINC seems to be doing ok healthwise, there are quite some concerns on its profitability.
VINC Financial Highlights
Over the last trailing twelve months VINC reported a non-GAAP Earnings per Share(EPS) of -20.2. The EPS decreased by -968.78% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -375.69% | ||
| ROE | -1104.04% | ||
| Debt/Equity | 0 |
VINC Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to VINC. The Buy consensus is the average rating of analysts ratings from 7 analysts.